Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/18/2025 | $162.00 | Sell → Neutral | Goldman |
| 5/15/2025 | Outperform → Perform | Oppenheimer | |
| 1/21/2025 | $186.00 | Perform → Outperform | Oppenheimer |
| 1/6/2025 | $139.00 | Neutral → Sell | Goldman |
| 9/12/2024 | $156.00 | Equal Weight | Wells Fargo |
| 4/11/2024 | $115.00 | Overweight → Neutral | JP Morgan |
| 1/11/2024 | Outperform → Perform | Oppenheimer | |
| 5/26/2023 | $87.00 | Perform → Outperform | Oppenheimer |
Goldman upgraded Hamilton Lane from Sell to Neutral and set a new price target of $162.00
Oppenheimer downgraded Hamilton Lane from Outperform to Perform
Oppenheimer upgraded Hamilton Lane from Perform to Outperform and set a new price target of $186.00
4 - Hamilton Lane INC (0001433642) (Issuer)
The Fund offers access to innovative private venture and growth investments not available in the public markets LONDON, Oct. 1, 2025 /PRNewswire/ -- Leading private markets investment firm Hamilton Lane (NASDAQ:HLNE) today announced the launch of the Hamilton Lane Global Venture Capital and Growth Fund ("HLGVG" or "the Fund"), an evergreen investment vehicle focused on growth and venture opportunities in the private markets. The Fund is available to certain individual investors and their advisors, as well as institutional investors, in parts of Europe, Asia, Latin America and the Middle East, as well as in Australia, New Zealand and Canada. HLGVG offers investors access to the firm's glo
RED BANK, N.J., Sept. 23, 2025 /PRNewswire/ -- PAX Health, a leading behavioral healthcare company backed by HCAP Partners and funds managed by Hamilton Lane (NASDAQ:HLNE), today announced its acquisition of Neuropsychology and Counseling Associates, a comprehensive outpatient mental health practice serving children, adolescents, adults, and families throughout New Jersey. This strategic acquisition enhances PAX Health's portfolio of specialized mental health services and expands its geographic footprint in New Jersey, strengthening the company's ability to deliver neuropsycho
The global evergreen fund for secondaries investment seeks to offer a diversified portfolio of mature private equity investments positioned for value creation by leveraging the firm's 24+ years of experience in the secondary market and extensive scaleThis launch marks the 10th fund in Hamilton Lane's $12 billion+ AUM evergreen platformLONDON, Sept. 3, 2025 /PRNewswire/ -- Leading private markets investment firm Hamilton Lane (NASDAQ:HLNE) today announced the launch of the Hamilton Lane Global Private Secondary Fund ("HLGPS" or "the Fund"), an evergreen investment vehicle focused on the secondary market. The Fund is available to accredited high-net-worth investors and their advisors, as well
3 - Hamilton Lane INC (0001433642) (Issuer)
4 - Hamilton Lane INC (0001433642) (Issuer)
4 - Hamilton Lane INC (0001433642) (Issuer)
8-K - Hamilton Lane INC (0001433642) (Filer)
8-K - Hamilton Lane INC (0001433642) (Filer)
424B5 - Hamilton Lane INC (0001433642) (Filer)
-- Experienced Industry Leader to drive Cosette's Best-in-Class Quality Organization and facilitate Regulatory Approvals -- Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it has appointed Jeff Neubig as Vice President, Quality and Regulatory Affairs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630266171/en/Jeff Neubig, VP, Quality & Regulatory Affairs, Cosette Pharmaceuticals In this critical role, Jeff will lead Cosette's best-in-class quality and regulatory affairs organizations, maintaining the company's rigorous quality standards and further establishing Co
Grenova, Inc., a Virginia-based innovator in sustainable laboratory technologies, today announced two significant milestones for the company: the appointment of Ted Hull to Grenova's board, and the successful completion of a new round of growth equity capital. These developments support Grenova's strategic vision to drive innovation, expand automation capabilities, and deliver transformative solutions to laboratories worldwide. Ted Hull brings over 30 years of experience in the life sciences industry, including as a clinical lab CEO for the last 20+ years. In his role at Grenova, Mr. Hull is set to provide strategic leadership and to play a pivotal role in shaping the company's future. "I
Industry leader with 35+ years of experience in manufacturing operations and global supply chain excellence Cosette Pharmaceuticals, Inc., a leading specialty pharmaceuticals company, today announced the appointment of Vincent (Vin) Colicchio as Senior Vice President of Operations, effective February 3, 2025. In this role, Vin will lead Cosette's manufacturing, global supply chain, and operational strategy, ensuring efficiency, and supply continuity as the company continues its strong trajectory of growth and transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250210366017/en/Senior Vice President, Operations (Photo
RED BANK, N.J., Sept. 23, 2025 /PRNewswire/ -- PAX Health, a leading behavioral healthcare company backed by HCAP Partners and funds managed by Hamilton Lane (NASDAQ:HLNE), today announced its acquisition of Neuropsychology and Counseling Associates, a comprehensive outpatient mental health practice serving children, adolescents, adults, and families throughout New Jersey. This strategic acquisition enhances PAX Health's portfolio of specialized mental health services and expands its geographic footprint in New Jersey, strengthening the company's ability to deliver neuropsycho
CONSHOHOCKEN, Pa., Aug. 5, 2025 /PRNewswire/ -- Leading private markets asset management firm Hamilton Lane Incorporated (NASDAQ:HLNE) today reported its results for the first fiscal quarter ended June 30, 2025. The Company issued a full detailed presentation of its first quarter fiscal 2026 results, which can be accessed on the Company's Shareholders website at https://shareholders.hamiltonlane.com/ Dividend Hamilton Lane has declared a quarterly dividend of $0.54 per share of Class A common stock to record holders at the close of business on September 19, 2025 that will be paid on October 6, 2025. The target full-year dividend of $2.16 represents a 10% increase from the prior fiscal year
CONSHOHOCKEN, Pa., July 15, 2025 /PRNewswire/ -- Hamilton Lane Incorporated (NASDAQ:HLNE) is scheduled to release financial results for the first fiscal quarter ended June 30, 2025 before the market opens on Tuesday, August 5, 2025. A copy of the earnings release and full detailed presentation will be available on the Hamilton Lane Shareholders website at https://shareholders.hamiltonlane.com/. Hamilton Lane will host a conference call via webcast at 11:00 a.m. ET on August 5 to discuss the results for the first fiscal quarter. For access to the live event via the webcast, visit Hamilton Lane's Shareholder's website by clicking here (https://shareholders.hamiltonlane.com/) at least 15 minut
SC 13G/A - Hamilton Lane INC (0001433642) (Subject)
SC 13G/A - Hamilton Lane INC (0001433642) (Subject)
SC 13G/A - Hamilton Lane INC (0001433642) (Subject)